Search Results - "CEDERMARK, G"

Surveillance vs. adjuvant therapy of clinical stage I testicular tumors – a review and the SWENOTECA experience by Cohn‐Cedermark, G., Stahl, O., Tandstad, T.

“…Summary Although clinical stage I (CS I) testicular cancer is highly curable, the optimal management is controversial. The aims of the Swedish and Norwegian…”
Get full text

Reply to ‘The challenge to one course carboplatin in seminoma clinical stage 1’ by Dieckmann and Anheuser by Tandstad, T., Cohn-Cedermark, G.

Get full text

Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA) by Tandstad, T., Ståhl, O., Dahl, O., Haugnes, H.S., Håkansson, U., Karlsdottir, Å., Kjellman, A., Langberg, C.W., Laurell, A., Oldenburg, J., Solberg, A., Söderström, K., Stierner, U., Cavallin-Ståhl, E., Wahlqvist, R., Wall, N., Cohn-Cedermark, G.

“…The purpose of the protocol was to reduce the treatment burden in clinical stage I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to…”
Get full text

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group by Tandstad, T., Ståhl, O., Håkansson, U., Dahl, O., Haugnes, H.S., Klepp, O.H., Langberg, C.W., Laurell, A., Oldenburg, J., Solberg, A., Söderström, K., Cavallin-Ståhl, E., Stierner, U., Wahlquist, R., Wall, N., Cohn-Cedermark, G.

“…SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin…”
Get full text

Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment by Weibring, K., Nord, C., Ståhl, O., Eberhard, J., Sandberg, K., Johansson, H., Arver, S., Giwercman, A., Cohn-Cedermark, G.

“…Little is known regarding sperm production following adjuvant treatment in testicular cancer (TC) clinical stage I (CS I) patients. A total of 182 TC patients…”
Get full text

Intermediate prognosis in metastatic germ cell tumors (IPGCT): Outcome and prognostic stratification by Seidel, C., Daugaard, K.G., Tryakin, A., Necchi, A., Cohn Cedermark, G., Ståhl, O., Hentrich, M., Brito, M., Albany, C., Taza, F., Gerl, A., Oechsle, K., Oing, C., Bokemeyer, C.

Get full text

Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer by Oldenburg, J., Aparicio, J., Beyer, J., Cohn-Cedermark, G., Cullen, M., Gilligan, T., De Giorgi, U., De Santis, M., de Wit, R., Fosså, S.D., Germà-Lluch, J.R., Gillessen, S., Haugnes, H.S., Honecker, F., Horwich, A., Lorch, A., Ondruš, D., Rosti, G., Stephenson, A.J., Tandstad, T.

“…Testicular cancer (TC) is the most common neoplasm in males aged 15 to 40 years and approximately 65%–75% have clinical stage I (CSI) disease. Both…”
Get full text

Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study by Tandstad, T., Cohn-Cedermark, G., Dahl, O., Stierner, U., Cavallin-Stahl, E., Bremnes, R.M., Klepp, O.

“…To offer minimized risk-adapted adjuvant treatment on a community and nationwide basis for patients with clinical stage 1 (CS1) nonseminomatous germ-cell…”
Get full text

An expression signature at diagnosis to estimate prostate cancer patients’ overall survival by Peng, Z, Skoog, L, Hellborg, H, Jonstam, G, Wingmo, I-L, Hjälm-Eriksson, M, Harmenberg, U, Cedermark, G C, Andersson, K, Ährlund-Richter, L, Pramana, S, Pawitan, Y, Nistér, M, Nilsson, S, Li, C

“…Background: This study aimed to identify biomarkers for estimating the overall and prostate cancer (PCa)-specific survival in PCa patients at diagnosis…”
Get full text

EAU Guidelines on testicular cancer: 2011 update by Albers, P, Albrecht, W, Algaba, F, Bokemeyer, C, Cohn-Cedermark, G, Fizazi, K, Horwich, A, Laguna, M.P

“…Abstract Context On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy, and follow-up of testicular cancer were…”
Get full text

2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma by Fischer, S, Tandstad, T, Weather, M, Fléchon, A, Aparicio, J, Klingbiel, D, Skrbinc, B, Shamash, J, Lorch, A, Basso, U, Dieckmann, K.P, Huddart, R, Cohn-Cedermark, G, Ståhl, O, Chau, C, Arriola, E, Laguerre, B, Maroto, P, Beyer, J, Gillessen, S

Get full text

Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors by Seidel, Christoph, Daugaard, Gedske, Tryakin, Alexey, Necchi, Andrea, Cohn Cedermark, Gabriella, Ståhl, Olof, Hentrich, Marcus, Brito, Margarida, Albany, Costantine, Taza, Fadi, Gerl, Arthur, Oechsle, Karin, Bokemeyer, Carsten

“…For metastatic germ cell tumour patients with intermediate prognosis (IPGCT) according to the IGCCCG classification 5-year overall survival (OS) rates of 79%…”
Get full text

SEMEN BANKING IN MEN WITH CANCER OR BENIGN DISEASES - A PROSPECTIVE COHORT by Weibring, K, Lundberg, F, Cohn-Cedermark, GC, Rodriguez-Wallberg, KA

Get full text

Inhibin B concentration is predictive for long‐term azoospermia in men treated for testicular cancer by Isaksson, S., Eberhard, J., Ståhl, O., Cavallin‐Ståhl, E., Cohn‐Cedermark, G., Arver, S., Lundberg Giwercman, Y., Giwercman, A.

“…Summary Azoospermia is a serious potential side effect following treatment for testicular cancer (TC). Our purpose was to examine possible predictors of…”
Get full text

7111 POSTER DISCUSSION High-dose Chemotherapy With Autologous Stem-cell Support in Patients With Metastatic Non-seminomatous Testicular Cancer -a Report From the Swedish Norwegian Testicular Cancer Group (SWENOTECA) by Hauqnes, H, Laurell, A, Stierner, U, Bremnes, R.M, Dahl, O, Cavallin-Stáhl, E, Cohn-Cedermark, G

Get full text

2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial by Bachner, M., Loriot, Y., Gross-Goupil, M., Zucali, P.A., Horwich, A., Germa-Lluch, J.-R., Kollmannsberger, C., Stoiber, F., Fléchon, A., Oechsle, K., Gillessen, S., Oldenburg, J., Cohn-Cedermark, G., Daugaard, G., Morelli, F., Sella, A., Harland, S., Kerst, M., Gampe, J., Dittrich, C., Fizazi, K., De Santis, M.

“…2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) has been recommended in international guidelines in the evaluation of postchemotherapy…”
Get full text

Results from SWENOTECA V: A population-based protocol for seminomatous testicular cancer by Tandstad, T., Småland, R., Klepp, O. H., Cavallin-Stahl, E., Stierner, U., Laurell, A., Flodgren, P., Dahl, O., Cohn-Cedermark, G.

“…Abstract only…”
Get full text

Clinical Results In 1004 Patients with Localized Prostate Cancer Treated with External Beam Radiotherapy, High Dose-rate 192-iridium Brachytherapy Boost, and Neo-adjuvant Hormonal Therapy by Castellanos, E, Cohn-Cedermark, G, Hjelm-Eriksson, M, Nilsson, J, Lundell, M, Lundell, G, Levitt, S, Kälkner, K, Nilsson, S

Get full text

Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program (vol 27, pg 2122, 2009) by Tandstad, T, Dahl, O, Cohn-Cedermark, G, Cavallin-Stahl, E, Stierner, U, Solberg, A, Langberg, C, Bremnes, RM, Laurell, A, Wijkstrom, H, Klepp, O

Get full text

Location and histology of retroperitoneal metastases in post-chemotherapy retroperitoneal lymph node dissection for non-seminoma germ cell tumour by Gerdtsson, A., Thor, A., Grenabo, A., Almås, B., Negaard, H.F.S., Glimelius, I., Halvorsen, D., Karlsdóttir, Á., Haugnes, H.S., Andreassen, K.E., Larsen, S.M., Holmberg, G., Wahlqvist, R., Tandstad, T., Cohn-Cedermark, G., Ståhl, O., Kjellman, A.

Get full text